Manfred Rüdiger
Directeur/Membre du Conseil chez 4SC AG
Provenance du réseau au premier degré de Manfred Rüdiger
| Entité | Type d'entité | Industrie | |
|---|---|---|---|
Eberhard Karls Universität Tübingen
31
| College/University | Other Consumer Services | 31 |
20
| Public Company | Biotechnology | 20 |
Technische Universität Braunschweig
12
| College/University | Other Consumer Services | 12 |
Ariceum Therapeutics GmbH
 Ariceum Therapeutics GmbH Miscellaneous Commercial ServicesCommercial Services Ariceum Therapeutics GmbH is a German clinical stage radiopharmaceutical company that focuses on the diagnosis and precision treatment of certain neuroendocrine and other aggressive, hard-to-treat cancers. Ariceum Therapeutics is based in Berlin, DE, and has subsidiaries in various locations worldwide. The company's lead targeted systemic radiopharmaceutical product, -satoreotide tetraxetan ("satoreotide"), is an antagonist of the somatostatin type 2 (sstr2) receptor, which is overexpressed in neuroendocrine tumors (NETs) and some aggressive cancers such as small cell lung cancer (SCLC) and Merkel cell carcinoma. Ariceum is also developing a radiolabeled PARP-inhibitor (ATT-001), which is slated to enter the clinic in early 2024. The company was founded in 2021, and Manfred Rüdiger has been the CEO of the company since 2021.
9
| Holding Company | Miscellaneous Commercial Services | 9 |
Thermosome GmbH
 Thermosome GmbH Pharmaceuticals: MajorHealth Technology Thermosome GmbH develops novel drugs for solid tumors. Its technology is used for delivery of various active pharmaceutical ingredients with its application in localized diseases. The company was founded by Lars Lindner, Martin Hossan and Hansjoerg Eibl and is headquartered in Planegg, Germany.
7
| Holding Company | Pharmaceuticals: Major | 7 |
| Extinct | Pharmaceuticals: Major | 6 | |
Cardion GmbH
 Cardion GmbH Medical SpecialtiesHealth Technology Cardion GmbH develops biopharmaceutical products. It integrates synergistic local gene delivery stem cell engineering and tolerance induction capabilities to build cardiovascular gene therapy products. The company is headquartered in Dusseldorf, Germany.
3
| Private Company | Medical Specialties | 3 |
Minaris Regenerative Medicine GmbH
 Minaris Regenerative Medicine GmbH BiotechnologyHealth Technology apceth Biopharma GmbH operates as a contract development & manufacturing organization. The firm specializes in cell-based and gene therapy products (Advanced Therapy Medicinal Products, ATMPs). Its GMP services include quality management, quality control, assay development, process development, cell banking & formulation and project management. The company was founded in 2007 and is headquartered in Munich, Germany.
3
| Subsidiary | Biotechnology | 3 |
Kiadis Pharma BV
 Kiadis Pharma BV Pharmaceuticals: MajorHealth Technology Kiadis Pharma BV operates as a is a clinical stage biopharmaceutical company focused on research, development and future commercialisation of cell-based immunotherapy products for the treatment of blood cancers and inherited blood disorders. Its products include: ATIR101 and ATIR201. The firm’s products are based on hematopoietic blood-forming stem cell transplants from donors. The company was founded in 1997 and is headquartered in Amsterdam, the Netherlands.
2
| Extinct | Pharmaceuticals: Major | 2 |
Igeneon AG
1
| Private Company | 1 | |
t2cure GmbH
 t2cure GmbH Medical/Nursing ServicesHealth Services t2cure GmbH develops progenitor cell-based regenerative therapeutics to provide new treatment options to patients suffering from cardiovascular diseases like myocardial infarction or peripheral vascular diseases. The company was founded by Andreas M. Zeiher and Stefanie Dimmeler n 2005 and is headquartered in Frankfurt, Germany.
1
| Extinct | Medical/Nursing Services | 1 |
LSP Services Deutschland GmbH
1
| Subsidiary | Investment Managers | 1 |
G2M Cancer Drugs AG
 G2M Cancer Drugs AG Miscellaneous Commercial ServicesCommercial Services Part of Valerio Therapeutics SA, G2M Cancer Drugs AG is a German company that researches new anti-cancer therapeutics and develops selected late-stage products. The company is based in Frankfurt am Main, Germany. G2M Cancer Drugs was acquired by Topotarget A/S on March 01, 2005.
1
| Subsidiary | Miscellaneous Commercial Services | 1 |
Graphique Sociétés connectées au second degré
Relation dans plusieurs entreprises
Sociétés connectées à Manfred Rüdiger via son réseau personnel
| Société | Secteur | Personnes liées | Poste principal |
|---|---|---|---|
| PFIZER, INC. | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
| MERCK KGAA | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| BAYER AG | Pharmaceuticals: Major | Director of Finance/CFO Corporate Officer/Principal | |
| 3I GROUP PLC | Investment Managers | Director/Board Member Corporate Officer/Principal | |
| SIEMENS AG | Industrial Machinery | Chief Tech/Sci/R&D Officer Corporate Officer/Principal | |
Genzyme Corp.
 Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Medical Specialties | Corporate Officer/Principal Corporate Officer/Principal | |
| VECTURA GROUP | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| AFFIMED N.V. | Biotechnology | Director/Board Member Director/Board Member Director/Board Member | |
| GSK PLC | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
| EVOTEC SE | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer Director of Finance/CFO | |
| MEDIGENE AG | Biotechnology | Director/Board Member Director/Board Member Investor Relations Contact | |
| STRATEC SE | Medical Specialties | Director of Finance/CFO Director/Board Member | |
LSP Management Group BV
 LSP Management Group BV Investment ManagersFinance LSP Management Group BV (LSP) is an independent European venture capital firm which was founded by Martijn Kleijwegt, Frits van der Have and Tom Schwarz in 1998. Headquartered in Amsterdam, the firm provides financing to early- to mid-stage life science companies. | Investment Managers | Founder Corporate Officer/Principal Private Equity Investor | |
| University of Freiburg | College/University | Undergraduate Degree Doctorate Degree | |
Sandoz AG
 Sandoz AG Pharmaceuticals: GenericHealth Technology Part of Novartis AG, Sandoz AG is a Swiss company that develops generic medicines and biosimilars. The company is based in Basel, Switzerland. | Pharmaceuticals: Generic | President Corporate Officer/Principal | |
Shire Orphan Therapies GmbH
 Shire Orphan Therapies GmbH Pharmaceuticals: MajorHealth Technology Shire Orphan Therapies GmbH engages in the development, manufacture, and distribution of chemical and biochemical products, ingredients, as well as pharmaceutical and diagnostic products. The company was founded in 1994 and is headquartered in Berlin, Germany. | Pharmaceuticals: Major | Director of Finance/CFO Chief Tech/Sci/R&D Officer | |
| University of Vienna | College/University | Doctorate Degree Doctorate Degree | |
| Technische Universität München | College/University | Undergraduate Degree Undergraduate Degree | |
vasopharm GmbH
 vasopharm GmbH Pharmaceuticals: MajorHealth Technology vasopharm GmbH operates as a pharmaceutical company. It discovers and develops novel therapeutics for the treatment of cerebro and cardiovascular diseases and their consequences. The firm focuses on therapeutics influencing the bioavailability of nitric oxide. The company was founded by Harald Schmidt and Ulrich Walter in July 1998 and is headquartered in Wuerzburg, Germany. | Pharmaceuticals: Major | Director/Board Member Chief Tech/Sci/R&D Officer | |
TopoTarget UK Ltd.
 TopoTarget UK Ltd. Drugstore ChainsRetail Trade TopoTarget UK Ltd. engages in the discovery and development of drugs and therapies to treat cancer. It develops anti-cancer drugs for molecular mechanisms associated with the cell cycle, chromatin control and DNA damage. The company was founded in 2002 and is headquartered in Oxford, the United Kingdom. | Drugstore Chains | Director/Board Member Corporate Officer/Principal | |
| University of Münster | College/University | Undergraduate Degree Undergraduate Degree Corporate Officer/Principal | |
| Ludwig-Maximilians-Universität München | College/University | Doctorate Degree Doctorate Degree | |
| Heinrich-Heine-Universität Düsseldorf | College/University | Doctorate Degree Doctorate Degree | |
Molten Ventures (Private Equity)
 Molten Ventures (Private Equity) Investment ManagersFinance Molten Ventures (Private Equity) (Molten Ventures) is a venture capital firm subsidiary of Molten Ventures Plc founded in 1998 by Simon Christopher Cook and Stuart Malcolm Chapman. The firm is headquartered in London, United Kingdom. | Investment Managers | Private Equity Investor Corporate Officer/Principal | |
| VIVORYON THERAPEUTICS N.V. | Biotechnology | Director/Board Member Chief Executive Officer Director/Board Member | |
Cellerix SA
 Cellerix SA Pharmaceuticals: GenericHealth Technology Founded in 2004, Cellerix is a biopharmaceutical company that develops innovative treatments based on cell therapy. Cellerix was founded within the Genetrix Group, group of biotechnology companies specialising in biomedicine. The Genetrix Group began its activities in 2001 at the National Centre for Biotechnology (CNB), which belongs to the Spanish Research Council (CSIC). One of the main objectives of Genetrix is to convert basic research results into therapeutic realities. Cellerix is leading the development of a new generation of medicines using expanded adult stem cells from adipose tissue (eASCs). Development is at a clinically advanced stage and the results from clinical trials in Phase I and II have been very promising. Obtaining these eASCs has big advantages because the process makes use of tissue that is almost always discarded from surgical procedures such as liposuction. eASCs have the capacity to activate physiological repair mechanisms through interaction with affected tissue. This technology represents a revolution in the treatment of some diseases that cannot satisfactorily be cured at present. Cellerix is working actively to adapt this new therapeutic strategy to treat autoimmune diseases such as inflammatory bowel disease. The main goal of the company is to market new tools for treating these diseases, which have a considerable negative impact of the quality of life of the sufferers. Cellerix also researches and develops medicines in other areas such as the development of skin equivalents, which are initially intended for the treatment of hereditary diseases such as epidermolysis bullosa. | Pharmaceuticals: Generic | Director/Board Member Chief Executive Officer | |
binx health, inc.
 binx health, inc. Information Technology ServicesTechnology Services Binx Health, Inc. develops and provides in vitro point-of-care (POC) testing on diseases such as sexually transmitted infections, neonatal sepsis and hospital acquired infections. Its technology products include in diagnostic and immunoassay platform, rapid POC, and nucleic acid detection technology. The company was founded by John Clarkson in 2005 and is headquartered in Trowbridge, the United Kingdom. | Information Technology Services | Director/Board Member Director/Board Member | |
SuppreMol GmbH
 SuppreMol GmbH Pharmaceuticals: MajorHealth Technology SuppreMol GmbH engages in the development and use of active substances for the therapy of autoimmune diseases and allergies, as well as the research on and development of medicinal products. It also produces medicines through licensed manufacturers. The products are supplied via pharmaceutical wholesale. The company was founded by Robert Huber, Uwe Jacob, and Peter Sondermann in 2002 and is headquartered in Berlin, Germany. | Pharmaceuticals: Major | Chief Executive Officer Director/Board Member | |
AiCuris GmbH & Co. KG
 AiCuris GmbH & Co. KG Miscellaneous Commercial ServicesCommercial Services AiCuris GmbH & Co. KG provides research and development services for antiviral and antibacterial agents. The firm develops drugs against viruses such as human cytomegalovirus, herpes simplex virus, hepatitis B virus and human immunodeficiency virus. The company was founded in March 2006 and is headquartered in Wuppertal, Germany. | Miscellaneous Commercial Services | Chief Executive Officer Director/Board Member | |
Concentro Management AG
 Concentro Management AG Investment ManagersFinance Concentro Management AG is a German company that offers services in corporate development and management. The private company is based in Munich, Germany. The company has offices in Munich, Leipzig, and Stuttgart. The company has supported various insolvency administrators in successful asset transfers and sales of companies. The company has also helped in the age-related succession plan of a shareholder of Ropro Produktions GmbH. Additionally, Concentro Management has increased EBIT and transparency in the group through a comprehensive restructuring program. | Investment Managers | Chairman Director/Board Member | |
| Julius-Maximilians-Universität Würzburg | College/University | Doctorate Degree Doctorate Degree Doctorate Degree | |
Eternygen GmbH
 Eternygen GmbH Pharmaceuticals: MajorHealth Technology Eternygen GmbH engages in the research and development of drugs. It develops new drugs for dietary-related metabolic diseases which include obesity, diabetes mellitus and fatty liver. The company was founded by Marco J. Janezic in June 2012 and is headquartered in Berlin, Germany. | Pharmaceuticals: Major | Chairman Director/Board Member | |
Pharvaris GmbH
 Pharvaris GmbH Pharmaceuticals: MajorHealth Technology Pharvaris GmbH operates as a clinical-stage company. It specializes in medicinal chemistry, drug discovery and development and hereditary angioedema. The company was founded by Berndt A. E. Modig, Jochen Knolle, Anne Lesage and Hans G. C. P. Schikan in October 2015 and is headquartered in Zug, Switzerland. | Pharmaceuticals: Major | Director/Board Member Founder Founder | |
| PHARVARIS N.V. | Pharmaceuticals: Major | Director/Board Member Founder Founder | |
| IMMUNIC, INC. | Pharmaceuticals: Major | Director/Board Member Chief Executive Officer Chief Tech/Sci/R&D Officer | |
Bristol-Myers Squibb GmbH & Co. KGaA
 Bristol-Myers Squibb GmbH & Co. KGaA Pharmaceuticals: MajorHealth Technology Part of Bristol Myers Squibb Co., Bristol-Myers Squibb GmbH & Co. KGaA is a German company that manufactures biopharmaceutical medicines. The company is based in Munich, Germany. The CEO of the company is Han Steutel. | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
| Verinos Pharmaceuticals GmbH | Director/Board Member Director/Board Member | ||
| Immunic Research GmbH | Chief Executive Officer Chief Executive Officer | ||
Aicuris Anti-Infective Cures AG
 Aicuris Anti-Infective Cures AG Miscellaneous Commercial ServicesCommercial Services Part of Santo Holding (Deutschland) GmbH, Aicuris Anti-Infective Cures AG aims to discover, develop, and deliver innovative, anti-viral drugs to immunocompromised patients aiming to prevent severe condition and life-threatening diseases. The company is based in Wuppertal, Germany. Aicuris has developed a commercial drug as well as pipeline of clinical-stage and pre-clinical anti-viral candidates. Its lead product Prevymis® (letermovir), a first-in-class non-nucleoside cytomegalovirus (CMV) inhibitor, was licensed to MSD and is commercialized for the prevention of human CMV infections in immunocompromised patients who underwent an allogeneic hematopoietic stem cell transplantation or kidney transplantation. Aicuris wholly owned product candidate, Pritelivir, targeting resistant herpes simplex virus (HSV) infections in immunocompromised patients, is in phase 3 clinical development. The German company was founded in 2006 by Helga Rübsamen-Schaeff. Larry G. Edwards has been the CEO of the company since 2023. | Miscellaneous Commercial Services | Founder Chairman | |
Binx Health Ltd.
 Binx Health Ltd. Miscellaneous Commercial ServicesCommercial Services Part of binx health, inc., Binx Health Ltd. is a British company that engages in research and development on biotechnology. The company is based in Trowbridge, UK. The company was founded in 2005. The CEO is Jeffrey R. Luber. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member | |
| Nouscom Srl | Miscellaneous Commercial Services | Director/Board Member Director/Board Member | |
Vectura GmbH
 Vectura GmbH Medical SpecialtiesHealth Technology Vectura GmbH manufactures and develops pharmaceutical therapies for airways diseases. It offers dry powder formulation technology, device technology, and development capabilities. The company was founded by Gerhard Scheuch in 1997 and is headquartered in Gemünden, Germany. | Medical Specialties | Director/Board Member Corporate Officer/Principal |
Statistiques
Internationale
| Allemagne | 29 |
| Royaume-Uni | 7 |
| Etats-Unis | 6 |
| Pays-Bas | 3 |
| Suisse | 3 |
Sectorielle
| Health Technology | 30 |
| Consumer Services | 8 |
| Finance | 5 |
| Commercial Services | 5 |
| Producer Manufacturing | 2 |
Opérationnelle
| Director/Board Member | 425 |
| Corporate Officer/Principal | 179 |
| Chief Executive Officer | 116 |
| Chairman | 103 |
| Independent Dir/Board Member | 49 |
Relations les plus connectées
| Insiders | |
|---|---|
| Helmut Jeggle | 47 |
| Per Anders Göte Samuelsson | 36 |
| Jörg Neermann | 34 |
| Martijn Kleijwegt | 33 |
| Andreas Hermann Renschler | 26 |
| Thomas Werner | 25 |
| Peter Stephen Keen | 25 |
| Stuart Chapman | 24 |
| Berndt A. E. Modig | 23 |
| Michael Meyer | 22 |
| Joachim Rothe | 22 |
| Olivier Litzka | 21 |
| Jason Loveridge | 20 |
| Martin C. Münchbach | 20 |
| Georgios Nikolaos Stamatelopoulos | 19 |
- Bourse
- Insiders
- Manfred Rüdiger
- Connexions Sociétés
